108 related articles for article (PubMed ID: 34086021)
1. Exploring the stability of inhibitor binding to SIK2 using molecular dynamics simulation and binding free energy calculation.
Shi M; Zhao M; Wang L; Liu K; Li P; Liu J; Cai X; Chen L; Xu D
Phys Chem Chem Phys; 2021 Jun; 23(23):13216-13227. PubMed ID: 34086021
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib-SIK2 Binding Elucidated by Homology Modeling, Molecular Docking, and Dynamics Simulations.
Shi M; Wang L; Li P; Liu J; Chen L; Xu D
ACS Omega; 2021 Apr; 6(16):11025-11038. PubMed ID: 34056256
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of SIK2 and SIK3 during differentiation enhances the anti-inflammatory phenotype of macrophages.
Darling NJ; Toth R; Arthur JS; Clark K
Biochem J; 2017 Feb; 474(4):521-537. PubMed ID: 27920213
[TBL] [Abstract][Full Text] [Related]
4. Salt-inducible kinase 2 regulates mitotic progression and transcription in prostate cancer.
Bon H; Wadhwa K; Schreiner A; Osborne M; Carroll T; Ramos-Montoya A; Ross-Adams H; Visser M; Hoffmann R; Ahmed AA; Neal DE; Mills IG
Mol Cancer Res; 2015 Apr; 13(4):620-635. PubMed ID: 25548099
[TBL] [Abstract][Full Text] [Related]
5. A potent inhibitor of SIK2, 3, 3', 7-trihydroxy-4'-methoxyflavon (4'-O-methylfisetin), promotes melanogenesis in B16F10 melanoma cells.
Kumagai A; Horike N; Satoh Y; Uebi T; Sasaki T; Itoh Y; Hirata Y; Uchio-Yamada K; Kitagawa K; Uesato S; Kawahara H; Takemori H; Nagaoka Y
PLoS One; 2011; 6(10):e26148. PubMed ID: 22022544
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel and selective SIK2 inhibitors by the application of AlphaFold structures and generative models.
Zhu W; Liu X; Li Q; Gao F; Liu T; Chen X; Zhang M; Aliper A; Ren F; Ding X; Zhavoronkov A
Bioorg Med Chem; 2023 Aug; 91():117414. PubMed ID: 37467565
[TBL] [Abstract][Full Text] [Related]
7. How to design potent and selective DYRK1B inhibitors? Molecular modeling study.
Szamborska-Gbur A; Rutkowska E; Dreas A; Frid M; Vilenchik M; Milik M; Brzózka K; Król M
J Mol Model; 2019 Jan; 25(2):41. PubMed ID: 30673861
[TBL] [Abstract][Full Text] [Related]
8. Computational insights into the binding of IN17 inhibitors to MELK.
Harger M; Lee JH; Walker B; Taliaferro JM; Edupuganti R; Dalby KN; Ren P
J Mol Model; 2019 May; 25(6):151. PubMed ID: 31069524
[TBL] [Abstract][Full Text] [Related]
9. Molecular dynamics simulations of the conformational plasticity in the active pocket of salt-inducible kinase 2 (SIK2) multi-state binding with bosutinib.
Shi M; Wang L; Liu K; Chen Y; Hu M; Yang L; He J; Chen L; Xu D
Comput Struct Biotechnol J; 2022; 20():2574-2586. PubMed ID: 35685353
[TBL] [Abstract][Full Text] [Related]
10. Extra precision docking, free energy calculation and molecular dynamics simulation studies of CDK2 inhibitors.
Tripathi SK; Muttineni R; Singh SK
J Theor Biol; 2013 Oct; 334():87-100. PubMed ID: 23727278
[TBL] [Abstract][Full Text] [Related]
11. Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity.
Alsamarah A; LaCuran AE; Oelschlaeger P; Hao J; Luo Y
PLoS One; 2015; 10(7):e0132221. PubMed ID: 26133550
[TBL] [Abstract][Full Text] [Related]
12. SIK2: A critical glucolipid metabolic reprogramming regulator and potential target in ovarian cancer.
Hu D; Du J; Xing Y; Cheng Y; He R; Liang X; Li H; Yang Y
J Obstet Gynaecol Res; 2023 Aug; 49(8):2000-2009. PubMed ID: 37317594
[TBL] [Abstract][Full Text] [Related]
13. Identification of Pak1 inhibitors using water thermodynamic analysis.
Biswal J; Jayaprakash P; Suresh Kumar R; Venkatraman G; Poopandi S; Rangasamy R; Jeyaraman J
J Biomol Struct Dyn; 2020 Jan; 38(1):13-31. PubMed ID: 30661460
[TBL] [Abstract][Full Text] [Related]
14. Designing of potent anti-diabetic molecules by targeting SIK2 using computational approaches.
Jayaprakash P; Biswal J; Rangaswamy R; Jeyakanthan J
Mol Divers; 2023 Jun; 27(3):1101-1121. PubMed ID: 35727438
[TBL] [Abstract][Full Text] [Related]
15. Salt-Inducible Kinase 2-Triggered Release of Its Inhibitor from Hydrogel to Suppress Ovarian Cancer Metastasis.
Hua Y; Yin H; Liu X; Xie J; Zhan W; Liang G; Shen Y
Adv Sci (Weinh); 2022 Aug; 9(22):e2202260. PubMed ID: 35618488
[TBL] [Abstract][Full Text] [Related]
16. 3D-QSAR-aided design of potent c-Met inhibitors using molecular dynamics simulation and binding free energy calculation.
Balasubramanian PK; Balupuri A; Bhujbal SP; Cho SJ
J Biomol Struct Dyn; 2019 May; 37(8):2165-2178. PubMed ID: 30044205
[TBL] [Abstract][Full Text] [Related]
17. SIK2 promotes ovarian cancer cell motility and metastasis by phosphorylating MYLK.
Shi X; Yu X; Wang J; Bian S; Li Q; Fu F; Zou X; Zhang L; Bast RC; Lu Z; Guo L; Chen Y; Zhou J
Mol Oncol; 2022 Jul; 16(13):2558-2574. PubMed ID: 35278271
[TBL] [Abstract][Full Text] [Related]
18. Designing New Kinase Inhibitor Derivatives as Therapeutics Against Common Complex Diseases: Structural Basis of Microtubule Affinity-Regulating Kinase 4 (MARK4) Inhibition.
Naz F; Shahbaaz M; Bisetty K; Islam A; Ahmad F; Hassan MI
OMICS; 2015 Nov; 19(11):700-11. PubMed ID: 26565604
[TBL] [Abstract][Full Text] [Related]
19. SIK2 promotes reprogramming of glucose metabolism through PI3K/AKT/HIF-1α pathway and Drp1-mediated mitochondrial fission in ovarian cancer.
Gao T; Zhang X; Zhao J; Zhou F; Wang Y; Zhao Z; Xing J; Chen B; Li J; Liu S
Cancer Lett; 2020 Jan; 469():89-101. PubMed ID: 31639424
[TBL] [Abstract][Full Text] [Related]
20. Exploring the interaction between human focal adhesion kinase and inhibitors: a molecular dynamic simulation and free energy calculations.
Zhan JY; Zhang JL; Wang Y; Li Y; Zhang HX; Zheng QC
J Biomol Struct Dyn; 2016 Nov; 34(11):2351-66. PubMed ID: 26549408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
